Collaboration｜StoneWise Presents AI-Powered Small Molecule R&D Technology at TEDA Seminar, Jointly Promoting High-Quality Industrial Development
This content is reprinted from "Tianjin Development Zone Technology" | StoneWise:
We would like to express our gratitude to the Science and Technology Bureau of Tianjin Binhai New Area and the Tianjin International Joint Academy of Biomedicine for their meticulous organization and invitation, as well as the wonderful sharing and valuable suggestions from all participants! StoneWise has been deeply engaged in the field of AI molecular generation for many years, accumulating solid practical experience and mature methodologies in model construction, technology iteration, and implementation operations.
We sincerely welcome industry peers to establish in-depth connections with us, deepen cooperation around customized model development, co-creation of innovative needs, and other directions, work together to address R&D pain points, and jointly promote the innovative development of the biopharmaceutical industry empowered by AI!
On the afternoon of October 30, the Science and Technology Innovation Bureau of Tianjin Economic-Technological Development Area (TEDA) jointly organized a seminar themed "AI Empowers Small Molecule Drug R&D" with the Tianjin International Joint Academy of Biomedicine. The core team from Beijing StoneWise Technology Co., Ltd. and representatives from 12 local biopharmaceutical innovation enterprises gathered to depict a new blueprint for AI-driven drug R&D.
At the seminar, the StoneWise team systematically demonstrated core technologies including AI molecular generation, activity prediction, and R&D pipeline acceleration & cost reduction, and shared cooperation cases with domestic and foreign pharmaceutical companies. Participating enterprises such as Hanmeng Testing, Ruichuang Kangtai, Pharma Pharmaceutical, Danna Bio, Quanhecheng Bio, and Chenxin Pharmaceutical conducted in-depth exchanges focusing on pain points such as data sharing, algorithm adaptation, and clinical translation.
In the next step, TEDA will focus on collaborative innovation and the transformation of scientific and technological achievements, accelerate the opening up of resources such as computing power, data, and scenarios, and rely on the Tianjin International Joint Academy of Biomedicine to continuously build a supply-demand docking platform for AI-empowered biopharmaceutical R&D. It will promote strengthened cooperation between AI drug R&D enterprises and local enterprises in links such as target discovery, lead compound optimization, and clinical protocol design, steadily advance AI-enabled industrial work, and provide effective support for the high-quality development of the regional biopharmaceutical industry.
About StoneWise
Founded in 2018, StoneWise is a technology company driving innovative drug R&D through artificial intelligence.
Based on in-depth industry insights into drug R&D, breakthroughs in the underlying theories of AI-driven drug discovery, advanced data governance for drug R&D, and strong software and engineering capabilities, StoneWise has built a small molecule drug design platform anchored by a multimodal AI 3D molecular generation large model. Built on the GPT/Transformer framework and integrated with geometric deep learning algorithms, this model can accurately generate molecules that fit the structure of target pockets, with capabilities that can be transferred to other drug modalities.
Leveraging this platform, the company has achieved significant results in its internal proprietary R&D pipeline, with some programs advancing to clinical trial stages. Additionally, nearly 100 pharmaceutical companies and research institutions have adopted the platform for early-stage drug R&D.
As a foundation model, it allows partners to fully integrate their own data, expertise, and models for customized iterations. Meanwhile, the entity library business derived from the foundation model is actively expanding both domestically and internationally.
